ArticleMedicine2026
Postoperative cutaneous metastasis of breast cancer with phenotypic conversion to triple-negative subtype: A case report.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleCutaneous breast cancer metastasis carries poor prognosis. Phenotypic conversion to a triple-negative subtype presents therapeutic challenges. Re-biopsy is crucial. PATIENT CONCERNS: A 53-year-old female underwent right modified radical mastectomy for HER2-positive invasive breast carcinoma in September 2023, and developed pruritic, erythematous nodules on the right chest wall, axilla, and back 9 months later. DIAGNOSES: Histopathology revealed poorly differentiated dermal carcinoma. The primary tumor was ypT2N3aMx with 23/23 positive nodes, grade 3. IHC showed ER(-), PR(-), HER2 (3+), and Ki-67 (~40%). In October 2023, a supraclavicular lymph node biopsy revealed HER2 IHC 0, representing the first evidence of phenotypic conversion. In July 2024, biopsy of the cutaneous metastatic lesion confirmed HER2 IHC 0 (no membrane staining), ER(-), PR(-), and Ki-67 (~60%+), consistent with a persistent triple-negative phenotype.
interventionsTreatment was switched to gemcitabine plus cisplatin combined with envafolimab (a PD-L1 inhibitor). Prior to initiation, PD-L1 IHC (SP263, Ventana) revealed TC 0%, IC+ <1%, and ICP ~10%. Six cycles were administered between August and November 2024. In January 2025, new lesions with ER 20% positivity emerged, and the regimen was adjusted to vinorelbine plus bevacizumab combined with envafolimab. OUTCOMES: The patient completed 6 cycles of gemcitabine plus cisplatin combined with envafolimab. Course was uneventful, with isolated grade 3 neutropenia (0.71 × 10^9/L) in October 2024. In January 2025, new cutaneous lesions emerged, prompting biopsy and regimen change. As of April 2025, the patient remained on active treatment with stable disease status. LESSONS: This case underlines re-biopsy importance. Conversion to a triple-negative phenotype necessitates complete change in systemic therapy. Phenotypic conversion may first manifest in lymph node metastases before becoming clinically evident in cutaneous lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.